Profit before tax increased 64.7% year on year to Rs 36.66 crore in Q4 FY23.
EBITDA stood at Rs 408 crore during the quarter, registering the growth of 58.3% as compared with Rs 258 crore posted in corresponding quarter last year. EBITDA margin was at 21.9% in Q4 FY23 as against 18% in Q4 FY22.
On full year basis, the company's net profit jumped 15.8% to Rs 83.29 crore on 18.6% rise in net sales to Rs 616.73 crore in FY23 over FY22.
During the year, 40 new customers added in advance pharmaceutical intermediates and 20 new customers were added in speciality chemicals.
Naresh Patel, executive chairman & managing director, Ami Organics, said, “Our full year total revenue grew by 19% YoY to Rs 621 crore. This was driven by Advance Pharmaceutical Intermediates business which grew strongly by 22% YoY.
We have used this challenging year to create various growth drivers for the coming yearsOne of the first initiatives was our electrolyte additives which have been approved by six clients and some of them have released plant scale trial orders. We are also expecting commercial orders from a few customers during the current quarter. Next initiative was to enter into long term exclusive contracts with customers and we have been able to sign some these contracts with some of our big customers. Third initiative was to expand product base for our specialty division with focus on products having high entry barriers.
I am also pleased to share the acquisition of 55% stake in Baba Fine Chemicals (BFC), a leading speciality chemicals company supplying products to the semiconductor industry. BFC has very niche products with high entry barriers, and we are excited to work with them and help them ramp-up their products at higher volumes."
The board has recommended a final dividend of Rs 3 per equity share for FY23, subject to approval of shareholders.
Surat-based Ami Organics is a R&D driven manufacturer of specialty chemicals with varied end usage, focussed on the development and manufacturing of advanced pharmaceutical intermediates (pharma intermediates) for regulated markets and generic active pharmaceutical ingredients (APIs) and New Chemical Entities (NCE) and key starting material for agrochemical and fine chemicals.
|